RxDoctor Payments Data

Pamela Karol

Psychiatric/Mental Health · Atlantic City, NJNPI 1174200323

Payments from drug & device makers

$1,395in general payments, 2019–2025

Across 42 payments — averaging $33.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$288
  • E.r. Squibb & Sons, L.L.C.$262
  • AbbVie$245
  • Neurocrine Biosciences, Inc.$185
  • Otsuka America Pharmaceutical, Inc.$169
  • Biogen$96
  • plus $150 from 3 others

What the payments were for

  • Food & beverage$1,17484%
  • Education$22116%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,395 in reported general payments places this provider in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$11,770
Medicare patients
33
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Risperdal ConstaRisperidone Microspheres11$25,368
RexultiBrexpiprazole12$16,664
Lurasidone Hcl16$8,540
Aripiprazole36$2,585
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$1,229
Hydroxyzine Pamoate40$944
Quetiapine Fumarate63$897
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$662
Bupropion XlBupropion Hcl38$655
Mirtazapine32$500
Divalproex Sodium ErDivalproex Sodium22$393
Trazodone Hcl80$390
Benztropine Mesylate28$388
Sertraline Hcl56$363
Divalproex Sodium13$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$169$16,66412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Atlantic City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →